China’s richest man, Glittering Zhong, is also the chairman of Nongfu Mountain Spring.
A-share listed Wantai Bio released an announcement that Chairman Zhong furtively resigned as chairman of the company and other positions for personal reasons, but is still the de facto controller, holding 75.15% of shares.
As a result of the news, by the close of trading on the 14th, Nongfu Shanquan’s share price fell 2.3%; Wantai Bio’s share price fell 9.66% and its market value evaporated RMB 12.054 billion (about USD 1.9 billion) in one day.
In addition to the identity of the chairman of Wantai Bio, Zhong Fur Fur Fur is also the chairman of Nongfu Shanquan, with a shareholding of 84.41% in Nongfu Shanquan.
In November 2020, the share price of Nongfu Shanquan, known as “Maotai in water,” set a new high, and Zhong furtively surpassed Alibaba founder Jack Ma and Tencent Holdings Chairman Ma Huateng to become China’s richest person due to his controlling stake in two listed companies, Nongfu Shanquan and Wantai Bio.
According to the official website as well as the prospectus and other official data, Wantai Bio, founded in 1991, is a company engaged in the research, production and marketing of in vitro diagnostic reagents, in vitro diagnostic instruments and vaccines, according to Punch News.
Wantai Bio was listed on the Shanghai Stock Exchange on April 29, 2020, and from the day of listing to June 5, it has reaped 24 consecutive trading days of halt, with a cumulative increase of 1319.20%.
Wantai Bio has several heavyweight products, such as the bivalent cervical cancer vaccine, the first domestic cervical cancer (HPV) vaccine to be listed in 2019.
During the New Crown epidemic, Vantaa Bio’s New Crown test reagents received the China Medical Device Registration Certificate and sold well. Wantai Bio’s 3Q2020 report then mentioned that revenue jumped 92.61%, mainly due to the addition of cervical cancer bivalent vaccine vaccine revenue, the addition of new crown reagent sales revenue, and the addition of technical cooperation revenue during the period.
It is worth noting that Wantai Bio also has a layout in the new crown vaccine, in September 2020, Wantai Bio had issued an announcement that the company, in cooperation with Xiamen University, the University of Hong Kong, the development of nasal spray influenza virus vector new crown pneumonia vaccine, recently obtained the State Drug Administration clinical trial application acceptance notice, and clinical trial approval agreed to this product for clinical trials.
A-share listed Wantai Biological released an announcement that Chairman Zhong Glitter resigned from his position as chairman of the company due to personal reasons.
Recent Comments